ABOUT

Cyprium Therapeutics, Inc. (Cyprium), a Fortress Biotech partner company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. In March 2017, Cyprium entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to advance the clinical development of Phase 3 candidate CUTX-101 (Copper Histidinate injection) for the treatment of Menkes disease.

In addition, Cyprium and NICHD entered into a worldwide, exclusive license agreement to develop and commercialize adeno-associated virus (AAV)-based gene therapy, called AAV-ATP7A, to deliver working copies of the copper transporter that is defective in Menkes patients, and to be used in combination with CUTX-101.

Both CUTX-101 and AAV-ATP7A gene therapy were granted orphan drug designation by the FDA. FDA granted Fast Track Designation and Rare Pediatric Disease Designation to CUTX-101. In July 2020, European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on the Orphan Medicinal Product Designation for CUTX-101.

Cyprium is a majority‐owned subsidiary of Fortress Biotech (NASDAQ: FBIO) and is based in New York City.